Promethazine detailed information

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
125px }}
Promethazine detailed information
Systematic (IUPAC) name
N, N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
Identifiers
CAS number 60-87-7
ATC code D04AA10 R06AD02, R06AD05
PubChem 4927
DrugBank APRD00601
Chemical data
Formula C17H20N2S 
Mol. mass 284.425 g/mol
Pharmacokinetic data
Bioavailability 88% absorbed but after first-pass metabolism reduced to 25% absolute bioavailability
Protein binding 93%
Metabolism Hepatic glucuronidation and sulfoxidation
Half life 16-19 hours
Excretion Renal and biliary
Therapeutic considerations
Pregnancy cat.

C(AU) C(US)

Legal status

P(UK) -only(US)
(injection POM(UK))

Routes Oral, rectal, IV, IM

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Promethazine is a first-generation H1 receptor antagonist antihistamine and antiemetic medication. It is a prescription drug in the United States, but is available over the counter in the United Kingdom, Switzerland, and many other countries (brand names Phenergan®, Promethegan®, Romergan, Fargan®, Prothiazine®).

Promethazine also has strong anticholinergic and sedative/hypnotic effects. Previously it was used as an antipsychotic, although it is generally not administered for this purpose now; promethazine has only approximately 1/10 of the antipsychotic strength of chlorpromazine.

Indications

Contraindications

  • Promethazine should not be given to children under two years of age; there is potential for fatal respiratory depression in this age group.
  • Hypersensitivity to Phenothiazines
  • Closed angle glaucoma
  • Intoxication with alcohol or other central depressants
  • Severe hypotension or shock
  • Coma due to any reason
  • Severely impaired liver function
  • Urine hesitancy due to enlargement of the prostate gland

Side effects

Typical side effects are:

  • Blurred vision
  • Confusion in the elderly
  • Drowsiness, dizziness, fatigue, more rarely vertigo
  • Dry mouth
  • Seizures (extremely rare)
  • Neuroleptic malignant syndrome (extremely rare)
  • Respiratory depression in patients under age of 2 and in those with severely compromised pulmonal function
  • Constipation

Dosage

Depending on disease and clinical condition (age, liver function):

  • Mild to moderate cases of agitation: 25–50 mg orally, 3 to 4 times daily
  • Insomnia: depending upon severity, 25–100 mg orally at bedtime

In pediatric patients doses as low as 5–10 mg, 3 times daily may suffice. For precise dosing syrup forms exist.

As an anti-emetic:

  • Adult: 6.25 mg IV, or 12.5 mg IM
  • Pediatric (greater than 2 years old): 0.25 mg/kg IV/ IM

Laboratory examinations

All patients should have their blood pressure measured frequently. During long-term therapy, blood cell counts, liver function studies, EKG, and EEG are recommended. The intervals should be determined according to the risk profile of the patient.

Recreational use

Promethazine is sometimes used as a recreational drug in conjunction with Codeine in prescription cough syrup. The mixture of Sprite and cough syrup with codeine, which is known as "purple drank", is popularized in the rap world, especially in the Houston area.[1]

External links

References

  • Basic and Clinical Pharmacology, 9th ed (2004). Katzung, Bertram G. pp. 264–265.

de:Promethazin hu:Prometazin nl:Promethazine nn:Prometazin ja:プロメタジンsv:Prometazin th:โปรเมทาซีน



WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
In other languages